SG10201510524TA - Cells expressing th1 characteristics and cytolytic properties - Google Patents

Cells expressing th1 characteristics and cytolytic properties

Info

Publication number
SG10201510524TA
SG10201510524TA SG10201510524TA SG10201510524TA SG10201510524TA SG 10201510524T A SG10201510524T A SG 10201510524TA SG 10201510524T A SG10201510524T A SG 10201510524TA SG 10201510524T A SG10201510524T A SG 10201510524TA SG 10201510524T A SG10201510524T A SG 10201510524TA
Authority
SG
Singapore
Prior art keywords
cells expressing
cytolytic properties
cytolytic
properties
expressing
Prior art date
Application number
SG10201510524TA
Other languages
English (en)
Inventor
Michael Har-Noy
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of SG10201510524TA publication Critical patent/SG10201510524TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
SG10201510524TA 2010-08-20 2011-08-22 Cells expressing th1 characteristics and cytolytic properties SG10201510524TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40188110P 2010-08-20 2010-08-20
US201161495055P 2011-06-09 2011-06-09

Publications (1)

Publication Number Publication Date
SG10201510524TA true SG10201510524TA (en) 2016-01-28

Family

ID=45594250

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013011069A SG187846A1 (en) 2010-08-20 2011-08-22 Cells expressing th1 characteristics and cytolytic properties
SG10201510524TA SG10201510524TA (en) 2010-08-20 2011-08-22 Cells expressing th1 characteristics and cytolytic properties

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013011069A SG187846A1 (en) 2010-08-20 2011-08-22 Cells expressing th1 characteristics and cytolytic properties

Country Status (18)

Country Link
US (3) US20120045423A1 (de)
EP (1) EP2606125B1 (de)
JP (2) JP6408219B2 (de)
KR (1) KR101900807B1 (de)
CN (2) CN108245673A (de)
AU (1) AU2011291477B2 (de)
BR (1) BR112013003989B1 (de)
CA (1) CA2808873C (de)
DK (1) DK2606125T3 (de)
ES (1) ES2660577T3 (de)
HU (1) HUE036094T2 (de)
IL (1) IL224813B (de)
NO (1) NO2606125T3 (de)
PL (1) PL2606125T3 (de)
PT (1) PT2606125T (de)
SG (2) SG187846A1 (de)
TR (1) TR201802334T4 (de)
WO (1) WO2012024666A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2606125T3 (de) * 2010-08-20 2018-04-21
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
ES2753259T3 (es) 2015-04-22 2020-04-07 Curevac Ag Composición que contiene ARN para el tratamiento de enfermedades tumorales
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的ｔ細胞の製造方法
US11730313B2 (en) * 2021-02-24 2023-08-22 Kirsten Wilkins Slow cooker liner system with integrated dividers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050392A1 (en) * 1998-09-22 2003-03-13 Brother Kogyo Kabushiki Kaisha Water-based ink for ink jetting and ink jet recording method
US20030194395A1 (en) * 2001-09-17 2003-10-16 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030134415A1 (en) 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
WO2003024312A2 (en) 2001-09-17 2003-03-27 Valeocyte Therapies Llc Cell therapy system
JP4699755B2 (ja) 2002-08-23 2011-06-15 ガブリエル ムルソフ， 腫瘍細胞におけるアポトーシスのＨｓｐ７０／Ｈｓｐ７０ペプチド依存性誘導物質としてのグランザイムＢの使用
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
DK2573166T3 (da) * 2004-02-26 2016-07-04 Immunovative Therapies Ltd Fremgangsmåder til fremstilling af T-celler til celleterapi
NO2606125T3 (de) 2010-08-20 2018-04-21

Also Published As

Publication number Publication date
AU2011291477B2 (en) 2016-07-28
HUE036094T2 (hu) 2018-06-28
US20120045423A1 (en) 2012-02-23
JP6525946B2 (ja) 2019-06-05
JP2013536232A (ja) 2013-09-19
DK2606125T3 (en) 2018-03-05
JP2017061558A (ja) 2017-03-30
CA2808873C (en) 2020-02-18
KR101900807B1 (ko) 2018-11-08
PL2606125T3 (pl) 2018-05-30
US10385315B2 (en) 2019-08-20
WO2012024666A3 (en) 2012-05-18
US20130196428A1 (en) 2013-08-01
EP2606125A2 (de) 2013-06-26
CN103068973A (zh) 2013-04-24
ES2660577T3 (es) 2018-03-23
KR20130103485A (ko) 2013-09-23
US20130195825A1 (en) 2013-08-01
WO2012024666A2 (en) 2012-02-23
SG187846A1 (en) 2013-03-28
EP2606125B1 (de) 2017-11-22
CA2808873A1 (en) 2012-02-23
IL224813B (en) 2020-06-30
TR201802334T4 (tr) 2018-03-21
EP2606125A4 (de) 2014-03-19
NO2606125T3 (de) 2018-04-21
JP6408219B2 (ja) 2018-10-17
PT2606125T (pt) 2018-02-27
BR112013003989A2 (pt) 2017-11-14
CN108245673A (zh) 2018-07-06
AU2011291477A1 (en) 2013-04-04
BR112013003989B1 (pt) 2020-11-24

Similar Documents

Publication Publication Date Title
HK1206004A1 (en) Ingenol-3-acylates iii and ingenol-3-carbamates -3- iii -3-
IL221511A (en) Arilatriazolones associated with bis aryl and their use
HK1184488A1 (en) Human facilitating cells and uses thereof
ZA201208173B (en) Peptices and their use
EP2603117A4 (de) Vernetzungshilfsmittel und verfahren dafür
GB201012175D0 (en) Procedure and mechanisms
EP2558137A4 (de) Verfahren und kombination
HRP20182083T1 (hr) Nova kombinacija i uporaba
EP2608785A4 (de) Lipomakrozyklen und deren verwendungen
EP2627391A4 (de) Hydrophobe katheter und zusammensetzung
PT2563806E (pt) Leucolectinas humanas e suas utilizações
IL222343A0 (en) Compositions comprising allogeneic th1 cells and uses thereof
SG10201510524TA (en) Cells expressing th1 characteristics and cytolytic properties
HK1201451A1 (en) Compositions and methods
GB201018650D0 (en) Methods and compositions
GB201017820D0 (en) Cells and devices
EP2529013A4 (de) Neuartige beta-glucosidase und verwendungen davon
EP2542967A4 (de) Hoch- und geringwertiger anwendungsstatus
EP2619571A4 (de) Menschliche b1-zellen und anwendungen davon
SG10201703686TA (en) Thioesterases and their use
EP2638160A4 (de) Nuclione und ribocapside
GB201001384D0 (en) Light-fitting and associated methods
GB201117299D0 (en) Zinc-oxygen cell and its application
GB201020268D0 (en) Composition and uses
ZA201104629B (en) Closure and closure arrangement